Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy

• Autor(a) principal: Bernardohanan
• Data de Publicação: 2010
• Outros Autores: Leonardo Maciel Fonseca, Magda Maria Profeta da Luz, Antonio Lacerda Filho, Mônica Maria Demas Álvares Cabral, Rodrigo Gomes da Silva
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/52817; https://orcid.org/0000-0002-5970-9570
• topic: Procedimentos Cirúrgicos de Citorredução; Neoplasias Colorretais; Quimioterapia Intraperitoneal Hipertérmica; Neoplasias Peritoneais; Procedimentos Cirúrgicos de Citorredução; Neoplasias Colorretais; Quimioterapia Intraperitoneal Hipertérmica; Neoplasias Peritoneais

Introduction: To evaluate the combined treatment with cytoreductive surgery and intraperi toneal chemotherapy for peritoneal carcinomatosis arising from colorectal cancer, pseudomyxoma peritonei and mesothelioma. Methods: Data were obtained from 73 patients with peritoneal carcinomatosis arising from colorectal cancer (52.1%), pseudomyxoma peritonei (41.1%) or mesothelioma (6.8%) between 2002 and 2011. We reported the morbidity grade (II, III and IV), mortality and survival rates of the candidates after cytoreductive surgery and intraperitoneal chemotherapy. Results: 41 (56.2%) women participated, and the median age was 50 years. Thirty nine patients (53.4%) underwent complete cytoreductive surgery and intraperitoneal chemotherapy. Patients who underwent a complete cytoreduction received intraperitoneal chemotherapy with mitomycin C, from which only 16/39 (41%) had hyperthermic intraperi toneal chemotherapy (41–42 ◦C). The overall morbidity rate was 23.3% and the grade III/IV complication rate was 12.3%. The overall mortality rate was 5.5%. The univariate analy sis showed that cytoreductive surgery and intraperitoneal chemotherapy (p = .029), a blood transfusion (p = .002) and the operative time (p = .001) were significant for the occurrence of postoperative complications. Patients with peritoneal carcinomatosis from colorectal cancer who underwent complete cytoreductive surgery and intraperitoneal chemotherapy had overall survival rates of 81.3%, 12.5% and 12.5% at 1, 3 and 5 years, respectively. Patients with peritoneal carcinomatosis from pseudomyxoma peritonei who underwent complete cytoreductive surgery and intraperitoneal chemotherapy had overall survival rates of 84.2%, 77.7% and 77.7% at 1, 3 and 5 years, respectively Conclusion: The combined treatment for peritoneal carcinomatosis may be performed safely with acceptable morbidity and mortality in a specialized unit setting. Although over half of patients underwent normothermic intraperitoneal chemotherapy, our results were compa rable to results from others centers.